Latest studies
- Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
This study is gathering important information about a rare kidney disease called atypical Hemolytic-Uremic Syndrome (aHUS). It looks at how the disease progresses and how safe new treatments like eculizumab and ravulizumab are for patients of all ages.
Atypical Hemolytic-Uremic SyndromeIsrael - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Israel - Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
This study is gathering information on a rare genetic condition called LAL Deficiency. It aims to understand the disease better and improve care for affected individuals, from babies to adults. It's a worldwide effort to collect health data over time.
Lysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Israel - Active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
Diffuse Cutaneous Systemic SclerosisInterstitial Lung DiseaseIsrael - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerIsrael - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
Urinary Bladder NeoplasmsMuscle-Invasive Bladder CancerIsrael - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisIsrael - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisIsrael - Recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
This study looks at how a new drug called epcoritamab works for adults with Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in real-life settings. It aims to see how well it treats these blood cancers when given as part of regular care.
Diffuse Large B-cell LymphomaFollicular LymphomaIsrael - RecruitingPHASE3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study looks at a long-term eye implant to treat 'wet' age-related macular degeneration (nAMD). It checks the safety of the implant and how well it works over time in people who have been in previous studies. It also explores ways to manage potential side effects.
Neovascular Age-Related Macular DegenerationIsrael - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
Community-acquired Pneumonia, Influenza, COVID-19Israel - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerIsrael - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
Neoplasm MalignantIsrael - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Israel - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This study is looking into a new medication called efruxifermin for people with a kind of liver disease called NASH/MASH and scarring (fibrosis). It's a large study where some people get the medication, and others get a dummy treatment, to see if it's safe and helps improve the liver condition.
NASH With FibrosisMASH With FibrosisIsrael - Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
Relapsed or Refractory Multiple MyelomaIsrael - Active not recruitingPHASE2
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
This study is testing a new medicine called sevasemten (also known as EDG-5506) for adults with Becker muscular dystrophy. It wants to see if the medicine is safe and if it helps people. Early parts of the study are now full, but one large part, GRAND CANYON, has also finished taking new participants.
Becker Muscular DystrophyIsrael - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungIsrael - Active not recruitingPHASE3
Linerixibat Long-term Safety, and Tolerability Study
This study looks at the long-term safety of a medicine called linerixibat for people with cholestasis, a liver condition that can cause severe itching. It's for patients who have already tried linerixibat in previous studies.
CholestasisIsrael - Recruiting
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
This study aims to understand how Parkinson's disease progresses by tracking changes in people with Parkinson's, those at risk, and healthy volunteers. Scientists hope to find new ways to measure the disease's progression, which will help develop better treatments.
Parkinson DiseaseIsrael - RecruitingPHASE1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
This study is testing a new gene-editing treatment called VERVE-102 for people with high cholesterol due to a genetic condition (Familial Hypercholesterolemia) or early heart disease. It aims to see if VERVE-102 is safe and can help lower 'bad' cholesterol.
Heterozygous Familial HypercholesterolemiaPremature Coronary Heart DiseaseIsrael - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaIsrael - RecruitingPHASE3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
This study is looking at a new medicine called sacituzumab govitecan (SG) for people with a type of lung cancer called extensive stage small cell lung cancer (ES-SCLC) that has been treated before. We want to see if SG works better than standard treatments to help people live longer.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)Israel - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
This study is looking into a new medication called BMS-986278 for people with progressive pulmonary fibrosis. It aims to see if the medication is safe and effective in slowing down this lung condition.
Progressive Pulmonary FibrosisIsrael - Active not recruitingPHASE2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
This study looks at a new medicine called sotatercept for a specific type of high blood pressure in the lungs (Cpc-PH) linked to heart failure. It's for people who were in a previous study to see how the medicine works long-term and if it's safe.
Hypertension, PulmonaryIsrael - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
Non-small Cell Lung CancerNSCLCIsrael - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
This study is looking at a new medicine called BMS-986278 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to see how well it works, if it's safe, and if people can tolerate it.
Idiopathic Pulmonary FibrosisIsrael - Active not recruitingPHASE2, PHASE3
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This study looks at a medicine called amlitelimab for moderate to severe eczema in people who've already tried it in other studies. We want to see how safe and effective it is over a long time, and if it continues to help.
Dermatitis AtopicIsrael - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisIsrael - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisIsrael - Active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
Dermatitis AtopicIsrael - RecruitingPHASE1, PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.
Ovarian CancerLung AdenocarcinomaEndometrial CancerLung Squamous Cell CarcinomaIsrael - Active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing new combinations of medicines for a type of blood cancer called Non-Hodgkin Lymphoma. It aims to see how safe and effective these new treatments are, and how the body handles them. It's for people whose cancer hasn't responded well to previous treatments.
Non-Hodgkin LymphomaIsrael - Active not recruitingPHASE3
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
This study is for people with a specific type of brain tumour called Grade 2 glioma, which has come back or wasn't fully removed by surgery. It's testing a new drug called vorasidenib against a dummy pill to see if it can help stop the tumour from growing.
Grade 2 GliomaResidual GliomaRecurrent GliomaIsrael - RecruitingPHASE2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
This study is looking at a new medicine called iptacopan for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see how well it works and if it's safe when added to standard treatments.
Lupus NephritisIsrael - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
This study is looking into a new medication called remibrutinib for people with a type of multiple sclerosis (MS) called Secondary Progressive MS (SPMS). It will check if the medicine is safe and helps slow down the disease.
Secondary Progressive Multiple Sclerosis (SPMS)Israel - RecruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)Solid TumorIsrael - Active not recruitingPHASE3
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
This study looks at a new medicine called Seladelpar for Primary Biliary Cholangitis (PBC). It's a long-term study to see how safe and effective it is over time. Participants will have taken Seladelpar in a previous study.
Primary Biliary CirrhosisIsrael - Recruiting
Vercise™ DBS Dystonia Prospective Study
This study looks at how well a device called Vercise Deep Brain Stimulation (DBS) works for people with dystonia. It aims to see if it helps with symptoms and improves daily life. The study monitors how patients do in real-life situations after having the device implanted.
DystoniaIsrael - Active not recruitingPHASE3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study looks at a new drug, astegolimab, for people with COPD who have flare-ups often. It compares the new drug to a dummy treatment (placebo) to see if it's safe and helps improve their breathing and reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)Israel - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionIsrael - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
Cervical CancerIsrael - Active not recruitingPHASE2
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
This study is looking into a new medicine called efinopegdutide for a liver condition called MASH. We want to see if it can help reduce liver fat, swelling, and scarring in people with MASH and mild scarring. It also checks how safe the medicine is.
Non-alcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisNAFLDMetabolic Dysfunction-associated Steatotic Liver DiseaseIsrael - Active not recruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaIsrael - RecruitingPHASE3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for children and teenagers aged 2 to 17 with moderately to severely active Crohn's disease. It checks how well the medicine works after a year in those who responded early on.
Crohn's DiseaseIsrael - RecruitingPHASE3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This 52-week study is testing a new drug, depemokimab, for adults with uncontrolled Hypereosinophilic Syndrome (HES). It aims to see if depemokimab is effective and safe compared to a placebo, alongside their usual HES treatment.
Hypereosinophilic SyndromeIsrael - RecruitingPHASE3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
This study is looking at a new medicine called Teplizumab for people aged 1 to 25 with a recent diagnosis of Stage 3 Type 1 Diabetes. It compares Teplizumab to a dummy medicine to see if it makes managing blood sugar easier and reduces how much insulin they need.
Type 1 Diabetes MellitusIsrael - RecruitingPHASE3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
This study looks at adding a new medicine, revumenib, to standard chemotherapy for people with a specific type of newly diagnosed acute myeloid leukaemia (AML) with a particular gene change (NPM1 mutation). It aims to see if this combination works better and is safe.
Acute Myeloid LeukemiasIsrael - RecruitingPHASE3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
This study is an extension of a previous trial for people with a condition called hereditary angioedema (HAE). It's looking at the long-term safety and how well a medicine, ADX-324, works for HAE types 1 and 2. Participants would have already taken part in the earlier study.
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2HAEIsrael - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
Urothelial CancerIsrael